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SUPPLEMENTARY NOTES
ABSTRACT
In this first annual review, we have demonstrated a clear role for the ARF tumor suppressor in regulating ribosome biogenesis in primary mouse mammary epithelial cells. Loss of ARF results in tremendous gains in rDNA transcription and rRNA processing. This mouse will be monitored over the next year for formation of breast tumors. We have also determined that ARF induction in the absence of the Tsc1 tumor suppressor is primarily achieved through increased translation of existing ARF mRNAs. We also made significant progress in our evaluation of p68 as a novel breast cancer oncoproteins that is suppressed by ARF. We have constructed a transgenic mouse overexpressing the ARF target p68 in the breast epithelium. We have shown that p68 causes increased ribosome biogenesis and that its expression is both required for the maintenance of proliferation in breast cancer cell lines and required for the transforming effects of oncogenic Ras in the absence of ARF.
INTRODUCTION
Cancers result from an inability of a cell to control its own growth. Normally, a cell interprets external and internal signals to create a balanced growth schedule. The main interpreters of these signals within a cell are called ARF and p53, and it falls on the shoulders of these two proteins to maintain normal cell growth. In this sense, both ARF and p53 are tumor suppressors that constantly monitor the growth state of the cell. In mouse and human cancers, loss of the ARF tumor suppressor is second only to mutation of p53, providing critical evidence of ARF's role in both monitoring and preventing the outbreak of cancer cells. A common target of ARF is the NPM/B23 oncogene, an abundant protein of the nucleolus. NPM normally responds to growth factors and, due to its nucleolar localization, is thought to transmit these growth signals to the maturing ribosome machinery. Cells lacking Arf exhibit tremendous gains in ribosome production and subsequent protein synthesis. Moreover, the entirety of this growth phenotype is dependent on NPM and p68DDX5 expression in the nucleolus, with loss of either capable of completely reversing the phenotype back to normal. This exciting new finding indicates that ARF is a master regulator of cell growth through its tight control of NPM-or DDX5-directed ribosome production and export. Importantly, we have found NPM overexpressed in nearly 50% of breast carcinomas that we have analyzed, implying that dysregulation of NPM may be a key event in promoting breast cancer development. In effect, tumor cells that require increased protein synthesis might accumulate more NPM or DDX5 in an attempt to increase ribosome output. It is our goal to determine whether NPM directly regulates ribosome maturation to promote breast cancer formation and to establish the importance of ARF in deterring this effect. We propose to now determine the complex roles of ARF, DDX5, and NPM in the nucleolus of breast epithelial cells and how they impact both ribosome biogenesis and cell growth to prevent and/or promote tumorigenesis.
This work has tremendous clinical implications as Arf (9p21) and p68DDX5 (17q24) reside on loci that are either deleted or amplified in ER+ resistant breast tumors, respectively. This fact makes our basic science on this interesting growth network directly applicable to the breast cancer phenotype/genotype.
BODY
As stated in the approved Statement of Work, we focused our energies on the tasks planned for Months 1-12. These included experiments outlined in Tasks 1 and 2. In this first Annual Progress Report, we detail the progress and results from these studies. During the first year, we have concentrated our efforts into establishing a cell culture model for loss of Arf function in MMECs. To this extent, we now have immortal Arf-/-MMECs that retain a diploid and genomically stable genotype. They are still sensitive to DNA damage pathway activation events such as UV and gamma irradiation. Using these cells, we have now begun our studies of ribosome biogenesis pathway activation in the absence of Arf. We have discovered that MMECs lacking Arf exhibit extremely high levels of 47S transcription (Figure 1 , top band). Additionally, Arf-null MMECs process rRNA at a considerably higher rate than wild-type counterparts, indicating that rRNA processing rates are elevated in the absence of Arf (Figure 1 ).
In the next year, we will build on this initial result to determine the mechanism for increased rDNA transcription and rRNA processing in MMECs lacking Arf. With this result in hand earlier than initially projected, we were able to begin some preliminary work on identifying the signaling pathway responsible for ARF induction.
f.
Identify the signaling pathway(s) responsible for enhanced ARF mRNA translation (Months 12-24)
Loss of Tsc1 results in hyperactivated mTOR signals, much the same as loss of Pten in primary MEFs. We first shifted to primary mouse embryonic fibroblasts (MEFs) because we had already previously established this cell type from Tsc1 fl/fl animals that were sent to us by Dr. David Kwiatkowski. Additionally, we have been unable to establish cultured MMECs from Tsc1 fl/fl animals due to technical difficulties in generating an efficient adenoviral Cre infection to effectively remove Tsc1. In the next year, we hope to overcome this difficulty and establish MMECs from these animals. When cultured in the presence of Cre-recombinase (adenoviral), Tsc1 is excised from both alleles. In this setting ARF protein is induced in a delayed mechanism (Figure 2) . This is agreement with our revised Statement of Work where I clearly stated that we would utilize RNA interference to lower PTEN or TSC1 to induce an ARF response. We had the Tsc1 fl/fl animals, so that is where we began. Knockdown for both of these genes has been weaker that 50%, prompting us to utilize a Cre-lox system instead. To determine the mechanism for ARF protein induction, we assayed the induction of ARF mRNA transcription following loss of Tsc1. Nine days following LacZ or Cre recombinase infection, cells were harvested and RNA was isolated. Northern blot analysis using probes specific for Arf exon 1 indicated that ARF mRNA expression was not increased upon loss of Tsc1 (Figure 3) , suggesting that any increase in ARF protein, as observed in Figure 2 , was not due to an increase in ARF mRNA transcription.
Given that ARF mRNA transcription was not altered in the absence of Tsc1, we sought to determine a post-transcriptional mechanism for ARF protein induction. Tsc1 fl/fl MEFs were radio-labeled with 35 Smethionine for various amounts of time, following a nine day infection with LacZ or Cre adenoviruses, to determine the rates of ARF translation. In the absence of Tsc1 (+Cre), ARF translation results in visible protein accumulation by 0.75 hours after radio-label addition compared to 4 hours for control cells (Figure 4) , indicating that ARF translation occurs at least 5 times faster in the absence of Tsc1. Wild-type and Tsc1 fl/fl MEFs were infected with LacZ or Cre adenoviruses for nine days. Total RNA was isolated from harvested cell pellets and separated on formaldehyde-agarose gels. Northern blot analysis using radio-labeled probes specific for murine Arf exon 1 revealed no change in ARF mRNA expression. Beta-Actin was used as a control (Task 1f). In the next year, we will strive to determine mechanism behind enhanced ARF translation in the absence of Tsc1 using modified MMECs. To begin this Task, we have generated a transgenic mouse overexpressing a Histidine-tagged NPM protein in mammary epithelial cells. This transgenic mouse contains a transgene Lox-stop-Lox (LSL)-His-NPM on a mixed background (C57Bl6/129). These mice were crossed into MMTV-Cre mice to generate LSL-His-NPM/MMTV-Cre mice that will overexpress a histidine-tagged NPM in mammary tissues. These mice were not generated with funds from this grant. We will utilize MMECs isolated from these mice to complete Task 2a as stated in our Statement of Work.
Due to our rapid progress with Task 1, we were able to move forward with some preliminary aspects of Task 3.
Task 3. Establish the oncogenic potential of the p68DDX5 RNA helicase (Months 24-48):
a. Determine whether p68 is required for ribosome biogenesis (Months 24-36).
In order to perform this task, we first wanted to establish the role for p68 in cell growth and proliferation using MEFs and established breast cancer cell lines. Once these data are in hand, we will be able to move forward with this task in years 2 and 3. We now know that overexpression of p68 causes an increase in both rDNA transcription ( Figure 5A ) and in rRNA processing (Figure 5B) , underscoring its importance in promoting ribosome biogenesis.
We next sought to determine whether p68 expression is required for breast cancer cell transformation. We used the ER-breast cancer cell line HCC1806 which expresses high levels of 68 without amplifying the DDX5 locus. We designed short interfering RNAs targeting the 3' region of p68 mRNA in order to perform RNA interference. Infection of HCC1806 cells with lentiviruses encoding p68 knockdown hairpins demonstrated our ability to effectively lower endogenous p68 levels in these cells (Figure 6 , top gel). Moreover, when we plated these infected cells in a limiting dilution of 5,000 cells per 100 mm, we observed a sharp decrease in cellular proliferation as judged by a lack of dividing cell foci (Figure 6 , lower panels). Our findings indicate that in this breast cancer cell line, p68 expression is required for cell proliferation. In the next year, we will expand these results to include several more breast cancer cell lines and to test their tumorigenicity in animals. Having shown a role for p68 in the maintenance of the transformed phenotype of HCC18068, we sought to move this type of experiment into a more genetically defined cell background. We infected Arf-/-MEFs with lentiviruses encoding p68 siRNAs and then re-infected these same cells 24 hours later with retroviruses encoding oncogenic RasV12. In the absence of Arf, RasV12 readily transformed cells as depicted by their ability to grow in soft agar (Figure 7) . However, in cells where p68 expression was greatly reduced with siRNAs against p68, RasV12 failed to transform and cells did not grow in soft agar (Figure 7 ). These data demonstrate a potentially novel role for p68 in assisting oncogenic Ras in the transformation of Arf-deficient cells. We will follow up on this exciting result next year using primary Arf-/-MMECs to determine the mechanism of action between Ras and p68.
Figure 7. p68 expression is required for RasV12-mediated cellular transformation. Arf -/-MEFs were infected with lentiviruses encoding siRNAs targeting the 3' region of mouse p68. These cells were infected 24 hours later with retroviruses encoding oncogenic RasV12. Twenty-four hours postinfection, cells were plated (3,000) into soft agar containing DMEM and 10% FBS. Soft agar plates were re-fed every 3 days and visualized at 10X microscopy 21 days later. Multi-cell colonies were counted in three separate fields by three individuals and graphed with error bars representing standard deviations n=3 (lower panel) (Task 3c). Once published, these mice will be available for free to any researcher that requests them.
Cell Lines: We have developed a unique primary mouse mammary epithelial cell (MMEC) line lacking the ARF tumor suppressor. These were established directly from Arf knockout mice on a pure C57Bl6 background. The Arf-null MMECs maintain a diploid phenotype and wild-type p53. These cells are spontaneously immortal and contain no artificial genes or plasmid constructs.
Funding Applied for: None
CONCLUSION
During the first year of funding, we have made significant progress on the Tasks outlined for Months 1-12. Due to our rapid progression, we have also begun Tasks for Months 12-24 regarding p68 function.
We have shown that Arf-null MMECs are immortal in cell culture models and that these cell lines do not contain aberrant chromosome numbers or alterations. They also maintain wild-type p53 and are quite capable of responding to typical p53-related stresses including gamma irradiation and hypoxia. These findings indicate that loss of Arf alone is sufficient to immortalize primary MMECs. These cells will prove to be a valuable tool to the general breast cancer research field.
In addition, we have shown that basic properties of ribosome biogenesis are altered in the absence of functional Arf. rDNA transcription and rRNA processing are both increased in the absence of basal ARF proteins, suggesting that ARF acts as a critical thermostat for ribosome levels in the cell. These results also argue that aberrant ribosome biogenesis might itself cause epithelial cell immortalization. This idea will be tested by my lab in the coming year.
We have also made significant progress in understanding the regulation of ARF levels in the cell. In the presence of hyperactive mTOR signaling, ARF protein is slowly induced. We now have shown that this induction is not due to increased transcription of ARF but rather in enhanced translation of existing ARF mRNAs. The question remains as to why this process occurs so slowly. We will begin assays aimed at answering this question in the next year.
Finally, we have begun our studies on the importance of the p68DDX5 RNA helicase in MMEC growth, demonstrating that established breast cancer lines require p68 expression to proliferate. Moreover, in primary MMECs, loss of p68 prevents their transformation by oncogenic Ras alleles, underscoring the overall importance of p68 expression in cellular transformation. We will build upon these results in the next year by generating a mouse model for p68 overexpression.
We have already generated a unique Arf knockout mouse model in the breast These will be invaluable resources for both the general breast cancer community and the future proposed studies in this grant.
